The Use of Feed Additives and Fungicides in the Agro-Industrial Complex in Light of the Antibiotic Resistance Problem. Part 1
https://doi.org/10.37489/0235-2990-2026-71-1-2-64-76
EDN: SYVQDX
Abstract
In the agro-industrial complex (AIC), it is recommended, whenever possible, to use the compounds that are considered not to have a significant impact on the problem of antibiotic resistance instead of antibiotic drugs that are undesirable from the point of view of the development of resistance of pathogenic microorganisms. Antibiotics are represented by different classes of compounds and have different mechanisms of action; they act as inhibitors of bacterial and fungal cell wall synthesis, protein synthesis, and cell membrane functions. A number of such antibiotics are considered as feed additives and growth promoters for the prevention of bacterial infections and accelerated growth of young animals, as well as fungicides in veterinary medicine and plant growing. Antibiotics come in a variety of classes and have different mechanisms of action; they act as inhibitors of bacterial and fungal cell wall synthesis, protein synthesis, and cell membrane function. This review presents the structures of these antibiotics, their mechanisms of action, and the potential for resistance development, including their impact on the human ecosystem.
About the Authors
E. N. Olsufyeva
Gause Institute of New Antibiotics
Russian Federation
Russian Federation
Evgenia N. Olsufyeva — D. Sc. in Chemistry, Professor, Chief Researcher at the Laboratory of Chemical Transformation of Antibiotics
Moscow
Scopus Author ID: 35595443300
WOS Research ID: B-1230-2017
RSCI Ausor ID: 57864
V. S. Yankovskaya
Russian State Agrarian University — Moscow Timiryazev Agricultural Academy
Russian Federation
Russian Federation
Valentina S. Yankovskaya — D. Sc. in Technical Sciences, Professor of the Department of Quality Management and Commodity Science
Moscow
ResearcherID: AAR-2725-2021
AuthorID: 562520
ScopusAuthor ID: 57195148578
References
1. Shchekotikhin AE, Olsufyeva EN, Yankovskaya VS. Antibiotiki i rodstvennye soedineniya. Nauchnoe izdanie. Moscow: Laboratoriya Znanij, 2022; 511. (in Russ.)]. ISBN 978-5-93208-247-8.
2. Olsufyeva EN, Yankovskaya VS. Analysis of the problem of antibiotic resistance in the agricultural sector. Antibiotiki i Khimioter. 2024; 69 (9–10): 108–132.(in Russ.)]. doi: https://doi.org/10.37489/02352990-2024-69-9-10-108-132].
3. Butaye P, Devriese LA, Haesebrouck F. Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on grampositive bacteria. Clin Microbiol. Rev. 2003; 16 (2): 175–188. doi: 10.1128/CMR.16.2.175–188.2003.
4. Yin X, Zabriskie TM. The enduracidin biosynthetic gene cluster from Streptomyces fungicidicus. Microbiology (Reading). 2006; 152: 2969–2983. doi: 10.1099/mic.0.29043-0.
5. Zhang J, He Z, Xu J, Song S, Zhu Q, Wu G, et al. Semi-rational mutagenesis of an industrial Streptomyces fungicidicus strain for improved enduracidin productivity. Appl Microbiol Biotechnol, 2020; 104: 3459–3471. doi: 10.1007/s00253-020-10488-0.
6. Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S. The mechanism of action of ramoplanin and enduracidin. Mol BioSyst. 2006; 2 (1): 69–76. doi: 10.1039/b515328j.
7. https://rubikonvet.by/ru/drugs/enramicin-8-porosok
8. Wallhausser KH, Nesemann G, Prave P, Steigler A. Moenomycin, a new antibiotic. I. Fermentation and isolation. Antimicrob Agents Chemother. (Bethesda), 1965; 5: 734–736. PMID: 5883490.
9. King DT, Wasney GA, Nosella M, Fong A, Strynadka NCJ. Structural Insights into Inhibition of Escherichia coli Penicillin-binding Protein 1B. J Biol Chem. 2017; 292 (3): 979–993. doi: 10.1074/jbc.M116.718403
10. https://www.vidal.ru/veterinar/flavomycin-80-27907
11. Kofoed CB, Vester B. Interaction of avilamycin with ribosomes and resistance caused by mutations in 23S rRNA. Antimicrob Agents Chemother. 2002; 46 (11): 3339–3342. doi: 10.1128/AAC.46.11.3339-3342.2002
12. Kyriakis SC. The effect of avilamycin in the control of stress induced post-weaning diarrhea in piglets. J Vet Pharmacol Ther. 1989; 12: 296–301.
13. Birgand G. Glycopeptide resistant enterococci: What’s the problem? Current Anaesthesia & Critical Care. 2009; 20 (5–6): 248–250. doi: 10.1016/j.cacc.2009.07.001.
14. McNicholas PM, Najarian DJ, Mann PA, Hesk D, Hare RS, Shaw KJ, et al. Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000; 44 (5): 1121–1126. doi: 10.1128/AAC.44.5.1121-1126.2000.
15. Krupkina M, Wekselmana I, Matzova D, Eyala Z, Posnera YD, Rozenberg H, et al. Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA binding. Proc Natl Acad Sci U S A. 2016; 113 (44): E6796–E6805. doi: 10.1073/pnas.1614297113.
16. Klimenko AV. Alternativy antibiotikam v zhivotnovodstve. Kombikorma. 2021; 5: 66–69. (in Russ.)]. https://kombi-korma.ru/sites/default/files/2/05_21/2021_05_66-69.pdf
17. Reshenie Kollegii Evrazijskoj Ekonomicheskoj Komissii ot 13 fevralya 2018 goda № 28 (in Russ.)]. https://stylab.ru/directory/antimicrobials/avilamycin/
18. Herzog HL, Meseck E, Delorenzo S, Murawski A, Charney W, Rosselet JP. Chemistry of antibiotics from micromonospora. 3. Isolation and characterization of everninomicin D and B. Appl Microbiol. 1965; 13: 515–520. doi: 10.1128/am.13.4.515-520.1965.
19. Maertens JA. Sch-27899 (Schering-Plough Corp). IDrugs. 1999; 2: 446–453.
20. Mikolajka A, Liu H, Chen Y, Starosta AL, Márquez V, Ivanova M, et al. Differential effects of thiopeptide and orthosomycin antibiotics on translational GTPases. Chem Biol. 2011; 18 (5): 589–600. doi: 10.1016/j.chembiol.2011.03.010.
21. Belova L, Tenson T, Xiong L, McNicholas PM, Mankin AS. A novel site of antibiotic action in the ribosome: interaction of evernimicin with the large ribosomal subunit. Proc Natl Acad Sci USA. 2001; 98 (7): 3726–3731. doi: 10.1073/pnas.071527498.
22. Panin AN, Komarov AA, Kulikovskij AV, Makarov DA. Problema rezistentnosti k antibiotikam vozbuditelej boleznej, obshchikh dlya cheloveka i zhivotnykh. Veterinariya i Zootekhniya: Veterinariya. 2017; 5: 18–24. (in Russ.)].
23. Arenz S, Juette MF, Graf M, Nguyen F, Huter P, Polikanov YS, et al. Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome. PNAS, 2016; 113 (27): 7527–7532. doi: 10.1073/pnas.1604790113
24. Haste M, Thienphrapa W, Tran DN, Loesgen S, Sun P, Nam S-J, et al. Activity of the thiopeptide antibiotic nosiheptide against contemporary strains of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo). 2012; 65 (12): 593–598. doi: 10.1038/ja.2012.77.
25. Zhu R, Yu X, Zhang T, Kong Y, Wang F, Jia J, et al. In vitro and intracellular inhibitory activities of nosiheptide against Mycobacterium abscessus. Front Microbiol. 2022; 13: 926361. doi: 10.3389/fmicb.2022.926361.
26. Cundliffe E, Thompson J. The Mode of action of nosiheptide (multhiomycin) and the mechanism of resistance in the producing organism. J Gen Microbiol. 1981; 126 (1): 185–192. doi:10.1099/00221287-126-1-185.
27. https://www.nita-farm.ru/produktsiya/nozif
28. Baumann S, Schoof S, Bolten M, Haering C, Takagi M, Shinya K, et al. Molecular determinants of microbial resistance to thiopeptide antibiotics. JACS. 2010; 132 (20): 6973–6981. doi: 10.1021/ja909317n.
29. Yin S, Jiang H, Chen D, Murchie AIH. Substrate recognition and modification by the nosiheptide resistance methyltransferase. PLoS one. 2015; 10 (4): e0122972. doi: 10.1371/journal.pone.0122972.
30. Dewey RS, Arison BH, Hannah J, Shih DH, Albers-Schönberg G. The structure of efrotomycin. J Antibiot (Tokyo). 1985; 38 (12): 1691–1698. doi: 10.7164/antibiotics.38.1691.
31. Stutz MW, Johnson SL, Judith FR, Miller BM. In vitro and in vivo evaluations of the antibiotic efrotomycin. Poult Sci. 1983; 62 (8): 1612–1618. doi: 10.3382/ps.0621612.
32. Landini P, Bandera M, Soffientini A, Goldstein BP. Sensitivity of elongation factor Tu (EF-Tu) from different bacterial species to the antibiotics efrotomycin, pulvomycin and MDL 62879. J Gen Microbiol. 1993; 139 (4): 769–774. doi: 10.1099/00221287-139-4-769.
33. Kimishima A, Hagimoto D, Honsho M, Watanabe Y, Iwatsuki M, Tsutsumi H, et al. Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox. Bioorg Med Chem Lett. 2022; 69: 128779–128784. doi: 10.1016/j.bmcl.2022.128779.
34. Tate RL, Halley BA, Taub R, Green-Erwin ML, Chiu SHL. Efrotomycin interaction with soil clay and organic matter fractions. J Agric Food Chem. 1989; 37 (4): 1165–1169. doi: https://doi.org/10.1021/jf00088a076.
35. Jackson KE, Pogula PK Patterson SE. Polyoxin and nikkomycin analogs: Recent design and synthesis of novel peptidyl nucleosides. Heterocyclic Commun. 2013; 19 (6): 375–386. doi: 10.1515/hc-2013-0141.
36. Osada H. Discovery and applications of nucleoside antibioticsbeyond polyoxin. J Antibiot. 2019; 72 (12): 855–864. doi: 10.1038/s41429-0190237-1.
37. Varnava KG, Ronimus RS, Sarojini V. A review on comparative mechanistic studies of antimicrobial peptides against archaea. Biotechnol Bioeng. 2017; 114 (11): 2457–2473. doi: 10.1002/bit.26387.
38. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive Aspergillosis. Clin Infect Dis. 2003; 37 (s3): S157–S187. doi: 10.1086/376523.
39. Winn M, Goss RJM, Kimura K, Bugg TDH. Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure–function studies and nucleoside biosynthesis. Nat Prod Rep. 2010; 27 (2): 279–304. doi: 10.1039/b816215h.
40. Ramirez-Ramirez N, Gutierrez-Corona F, Lopez-Romero E. Nikkomycin-resistant mutants of Mucor rouxii: physiological and biochemical properties. Antonie Van Leeuwenhoek. 1993; 64 (1): 27–33. doi: 10.1007/BF00870918.
41. Larwood DJ. Nikkomycin Z — ready to meet the promise? J Fungi. 2020; 6 (4): 261. doi: 10.3390/jof6040261.
42. https://pharmaoffer.com/ru/api-excipient-supplier/enzyme-replacements-modifiers/nikkomycin-z
43. Ceregeghetti DM, Carreira EM. Amphotericin B: 50 years of chemistry and biochemistry. Synthesis. 2006; 6: 914–942. doi: 10.1055/s-2006926368.
44. Kasumov KhM. Struktura i membrannaya funktsiya polienovykh makrolidnykh antibiotikov. DA Aliev (ed.). Moscow: ElmNauka. 2009; 512. (in Russ.)].
45. Vetlurina LA, Nikitina ET. Protivogribkovye polienovye antibiotiki. Alma-Ata: Nauka. 1980; 248. (in Russ.)].
46. Płosiński M, Laskowski T, Sowiński P, Pawlak J. Stereostructure of mycoheptin A2. Magn Reson Chem. 2012; 50 (12): 818–822. doi: 10.1002/mrc.3890.
47. https://www.med74.ru/infoitem5694.html
48. Shikova YuV, Likhoded VA, Likhoded TA. Uchebnoe posobie. Ufa: Izdvo GOU VPO «Bashgosmeduniversitet Roszdrava». 2010; 318. (in Russ.)].
49. Veterinarnaya farmakologiya. Toksikologiya: praktikum. TV Burtseva, NG Kurochkina (eds.). Ekaterinburg: Izd-vo Uralskogo GAU. 2021; 136. (in Russ.)]. ISBN 978-5-87203-477-3.
50. https://www.rlsnet.ru/active-substance/mikogeptin-1471
51. Shenin YD, Daurenbekova AS, Morgunova AF, Vetlugina LA, Iakovlev AA. Structure of the pentaene antibiotic roseofungin. Antibiotiki i Meditsinskaya Biotekhnologiya. 1986; 31(5): 341–349. (in Russ.)].
52. Sadanov AK, Berezin VE, Kulmagambetov IR, Trenozhnikova, LP Balgimbaeva AS. RoseofunginAS, 2% ointment for the treatment of Tinea Pedis and Tinea Corporis: results of a randomized, single-blind, prospective, multicenter phase III clinical trial. Farmatsiya Kazakhstana. 2021; 5: 55–64. (in Russ.)].
53. https://drugs.medelement.com/drug/розеофунгин–ас-2-инструкция/40372161613464181?instruction_lang=RU
54. Sadanov AK, Akylova MА, Balgimbaeva AS, Ibragimova LN, Bekezhanova TS, Itemirova AO, et al. Activity of antibiotic roseofungin against clinical pathogens of vaginal candidiasis. News of the National Academy of Sciences of the Republic of Kazakhstan. 2018; 330 (6): 44–49]. (in Russ.)]. doi: https://doi.org/10.32014/2018.2518-1629.16.
55. Sadanov AK, Berezin VE,Kulmagambetov IR,Trenozhnikova LP, Balgimbayeva AS. New original drug Roseofungin-AS, ointment 2%. Pharmacy of Kazakhstan. 2021; 5 (238): 55–64. (in Russ.)]. doi: https://doi.org/10.53511/pharmkaz.2021.70.20.011.
56. Shi L, Nwet TT, Ge B, Zhao W, Liu B, Cui H, Zhang K. Antifungal and plant growth-promoting activities of Streptomyces roseoflavus strain NKZ-259. Biol Control. 2018; 125: 57–64. doi: 10.1016/j.biocontrol.2018. 06.012.
57. Sarkar DJ, Mukherjee I, Shakil NA, Rana VS, Kaushik P, Debnath S. Antibiotics in agriculture: use and impact. indian journal of ethnophytopharmaceuticals (IJEPP). 2018; 4 (1): 4–19. https://www.researchgate.net/publication/325010472
58. Lokhande PD, Gawai KR, Kodam KM, Waghmare BY, Chabukswar AR, Jagdale SC. Water soluble amide derivatives of polyene antibiotic and their antifungal activity. Trends in Applied Sciences Research. 2006; 1 (5): 529–533. https://scialert.net/abstract/?doi=tasr.2006.529.533
59. Sawant SD, Sawant IS, Banerjee K, Shetty D, Waghmare M, Kalbhor G, et al. Bio-efficacy of Aureofungin-sol in control of downy and powdery mildews in grape. J Hortl Sci. 2011;6 (2): 136–140. doi: 10.24154/jhs.v6i2.421.
60. Ghosh P. K. Revisiting novel active pharmaceutical ingredients from India. Achievements and Future Challenges. RIS 2021; 21. ISBN: 81-7122-164-5.
61. Misato T, Blasticidin S. In: Gottlieb D., Shaw PD. (eds) Mechanism of action. Antibiotics. 1967; 1. Springer, Berlin, Heidelberg. doi: 10.1007/9783-642-46051-7_32.
62. Hamer JE, Talbot NJ. Infection-related development in the rice blast fungus Magnaporthe grisea. Curr Opin Microbiol. 1998; 1 (6): 693–697. doi: 10.1016/s1369-5274(98)80117-3.
63. Svidritskiy E, Ling C, Ermolenkob DN, Korostelev AA. Blasticidin S inhibits translation by trapping deformed tRNA on the ribosome. PNAS; 2013, 110 (30): 12283–12288. doi: 10.1073/pnas.1304922110.
64. Izumi M, Miyazawa H, Kamakura T, Yamaguchi I, Endo T. Hanaoka, F. Blasticidin S-resistance gene (bsr): a novel selectable marker for mammalian cells. Exp. Cell Res. 1991; 197 (2): 229–233. doi: 10.1016/00144827(91)90427-v.
65. K’ominek LA. Cycloheximide production by Streptomyces griseus: control mechanisms of cycloheximide biosynthesis. Antimicrob Agents Chemother. 1975; 7(6): 856–6. doi: 10.1128/AAC.7.6.856.
66. Müller F, Ackermann P, Margot P. Fungicides, Agricultural, 2. Individual fungicides. ullmann’s encyclopedia of industrial chemistry. 2012. Weinheim: Wiley-VCH. doi: 10.1002/14356007.o12_o06.
67. Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol. 2010; 6 (3): 209–217. doi: 10.1038/nchembio.304.
68. Pizzol MD, Freitas EC, Locatelli C, Guareze F, Reginatto P, Machado G, et al. Drug Des Devel Ther. 2021; 15: 2091–2098. doi: 10.2147/DDDT.S298059.
69. DeFalco AP. Cycloheximide. Encyclopedia of Toxicology (Fourth Edition). 2024; 3: 411–415. doi: 10.1016/B978-0-12-824315-2.00626-6.
70. Syuhada NH, Merican F, Zaki S, Broady PA, Convey P, Muangmai N. Strong and widespread cycloheximide resistance in Stichococcus-like eukaryotic algal taxa. Sci. Rep., 2022; 12: 1080–1089. doi: 10.1038/s41598022-05116-y.
71. McCormick SP, Stanley AM, Stover NA, Alexander NJ. Trichothecenes: from simple to complex mycotoxins. Toxins. 2011; 3: 802–814. doi: 10.3390/toxins3070802.
72. Burakaeva AD. Mikofilnye griby v biotekhnologii fungitsidnykh preparatov. Vestnik OGU. 2014 (6): 98–103. (in Russ.)].
73. Wang W, Zhu Y, Abraham N, Li X-Z, Kimber M, Zhou T. The ribosomebinding mode of trichothecene mycotoxins rationalizes their structure — activity relationships. Int J Mol Sci. 2021; 22: 1604–1620. doi: 10.3390/ijms22041604
74. Egorov NS. Osnovy ucheniya ob antibiotikakh. Klassicheskij universitetskij uchebnik. Izd. MGU, Nauka. 2004; 528. (in Russ.)].
75. Ye W, Zhu M, Cen Y, Liu T, Li H, Liu. H, Zhang W. The excavation of novel toxin-resistance proteins against trichothecenes toxins in Paramyrothecium roridum. Int J Biol Macromol. 2021; 192: 369–378. doi: 10.1016/j.ijbiomac.2021.09.185.
76. Beekman AM, Barrow RA. Fungal metabolites as pharmaceuticals. Australian Journal of Chemistry. 2014; 67: 827–843. doi: 10.1071/CH13639.
77. Lana AJD, Pippi B, Carvalho AR, Moraes RC, Kaiser S, Ortega GG, et al. In vitro additive effect on griseofulvin and terbinafine combinations against multidrug-resistant dermatophytes. Braz J Pharm Sci. 2018; 54 (2): e17149. doi: 10.1590/s2175-97902018000217149.
78. Polak-Sliwinska M, Paszczyk B. Trichothecenes in food and feed, relevance to human and animal health and methods of detection: a systematic review. Molecules. 2021; 26 (2): 454–475. doi: 10.3390/molecules26020454.
79. Nardoni S, Mugnaini L, Papini R, Fiaschi M, Mancianti F. Canine and feline dermatophytosis due to Microsporum gypseum: a retrospective study of clinical data and therapy outcome with griseofulvin. J Mycol Med. 2013; 23 (3): 164–167. doi: 10.1016/j.mycmed.2013.05.005.
80. Petersen AB, Rønnest MH, Larsen TO, Clausen MH. The chemistry of griseofulvin. Chem Rev. 2014; 114 (24): 12088–12107. doi: 10.1021/cr400368e.
81. Danilenko RU, Khismatullina ZR, Mukhamadeeva OR. GriseofulvinResistant Forms of Tinea Anthropozoonosis. Allergologiya i Dermatologiya. 2015; 108 (7): 39–41. (in Russ.)].
82. https://vettorg.ru/catalog/item-1743.html
83. https://www.vidal.ru/drugs/griseofulvin__3692
84. Parrino B, Schillaci D, Carnevale I, Giovannetti E, Diana P, Cirrincione G, Cascioferro S. Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance. Eur J Med Chem. 2019; 161: 154–178. doi: 10.1016/j.ejmech.2018.10.036.
85. Reshenie komissii Evropejskogo Soyuza ot 23 iyunya 2023 g. N 70 O vnesenii izmenenij v nekotorye resheniya komissii tamozhennogo soyuza i soveta evrazijskoj ekonomicheskoj komissii». (in Russ.)]. https://www.alta.ru/tamdoc/18kr0028/ от 17.03.2018
86. Olsufyeva EN, Yankovskaya VS, Dunchenko NI. Review of risks of antibiotic contamination of dairy products. Antibiot Khimioter = Antibiotics and Chemotherapy. 2022; 67 (7–8): 82–96. doi: https://doi.org/10.37489/0235-2990-2022-67-7-8-82-96.]
87. Malagón-Rojas JN, Parra-Barrera EL, Lagos L. From environment to clinic: the role of pesticides in antimicrobial resistance. Rev Panam Salud Publica. 2020; 44: e44–e48. doi: 10.26633/RPSP.2020.44.
Review
For citations:
Olsufyeva EN, Yankovskaya VS. The Use of Feed Additives and Fungicides in the Agro-Industrial Complex in Light of the Antibiotic Resistance Problem. Part 1. Antibiotiki i Khimioterapiya = Antibiotics and Chemotherapy. 2026;71(1-2):64-76. (In Russ.) https://doi.org/10.37489/0235-2990-2026-71-1-2-64-76. EDN: SYVQDX
Views:
418
JATS XML
Email this article 